Valeant has finally made a significant M&A move after its failed pursuit of Allergan, and bankrupt Dendreon has finally found a way to unload cancer vaccine Provenge. And they're one and the same.
Gilead Sciences racked up another point in the pricing battle with its hep C rival AbbVie as UnitedHealth Group chose Harvoni as its preferred hepatitis C treatment over AbbVie's Viekira Pak, weeks after Gilead scored deals with three insurers to make Harvoni the primary option for patients. Read more >>
Hikma Pharmaceuticals is no stranger to buyout rumors. The Jordan-based drugmaker pops up often in deal talk, partly because of its sales and infrastructure in emerging markets. Now, there's another reason or two--its recent win on the gout drug Mitigare and its impending entry onto London's Financial Times Stock Exchange. New rumors, too. Read more >>
Alexion Pharmaceuticals has found its next CEO. With more than 25 years of experience in the biopharmaceutical industry, David Hallal, 48, is set to take the reins, effective April 1. Read more >>
POPULAR COMMENT THREADS
Eli Lilly CEO John Lechleiter promised today that the company's finances will improve over the next decade. It would be hard for them to get much worse. Lilly's fourth-quarter net income was down 41%. Its revenue was down 12%. Its earnings were down 40% to $0.40 a share.
So far, Sanofi has come up empty-handed in its hunt for a CEO to replace the ousted Chris Viehbacher. And the mystery surrounding his firing may have something to do with it.
AbbVie posted promising fourth-quarter earnings fueled by the strong performance of blockbuster Humira. But the company is looking beyond its top-selling med in 2015, focusing on the development of new products to bolster its bottom line as it counters generic competition to some of its key moneymakers.
Novo Nordisk CEO Lars Sorensen told investors today that 2014 had been a more challenging year than most, then rolled off a series of results that showed significant leaps in sales both in the U.S. and worldwide. He then waved off any worries about a price war in the U.S. being a significant issue for the world's largest maker of insulin products this year.
India's National Pharmaceutical Pricing Authority has told drugmakers that failure to hand in drug price and sales data by next week is not an option.
A significant new study of Roche's blockbuster flu fighter Tamiflu has found that, while it has side effects, it can reduce symptoms by a day and keep some patients out of the hospital with complications, Reuters reports.
From Our Sister Sites
As the med tech industry homes in on next-generation devices for peripheral artery disease, medical experts are questioning the necessity of procedures to treat the disease, pointing to large Medicare payments made to physicians performing the operations.
Scientists in Florida have found a virus in ticks that is connected to hemorrhagic fever, which was thought to have disappeared globally more than 40 years ago.